Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 23, 2015 7:58 AM ET


Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal, and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in...

1801 Century Park East

Suite 1820

Los Angeles, CA 90067

United States

Founded in 2004

5 Employees





Key Executives for Ritter Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 54
Founder, President and Director
Age: 31
Executive Chairman and Chief Strategic Officer
Age: 64
Chief Financial Officer
Age: 46
Senior Clinical & Regulatory Advisor
Compensation as of Fiscal Year 2014.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals, Inc. Appoints Gerald T. Proehl to its Board of Directors

Ritter Pharmaceuticals, Inc. announced that Gerald T. Proehl has joined the Company’s Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will chair the Company’s nominating and corporate governance committee. Mr. Proehl served as President, Chief Executive Officer and Director of Santarus, Inc. from 2002 through the company’s acquisition in January 2014 by Salix Pharmaceuticals, Inc. for $2.6 billion.

Ritter Pharmaceuticals, Inc. Appoints Paul V. Maier as a Board of Directors

Ritter Pharmaceuticals, Inc. appointed Paul V. Maier as a Board of Directors. Mr. Maier will chair the company’s audit committee. Mr. Maier served for five years as the Chief Financial Officer of life sciences company Sequenom, Inc. He previously served for 15 years as the Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. Mr. Maier currently serves on the Boards of Directors of International Stem Cell Corporation, Apricus Biosciences, MabVax Therapeutics and Biological Dynamics.

Ritter Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Ritter Pharmaceuticals, Inc. filed its S-1 on Mar 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Karo Bio USA, Inc. United States
FidoPharm, Inc. United States
ProThera Biologics LLC United States
SiCap Industries, LLC United States
Virologix Corp. United States

Recent Private Companies Transactions

Private Placement
December 4, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ritter Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at